Abstract
The aim of this study was to evaluate the effect of prior pneumococcal vaccination on the clinical outcome of 554 consecutive hospitalized adults with community-acquired pneumococcal pneumonia from 1995 to 2004, 61 of whom had been vaccinated in the 5 years before admission. Outcome variables that were compared in vaccinated and unvaccinated adults included the occurrence of bacteremia, the time to resolution of pneumonia symptoms, the length of hospital stay, and mortality. Prior pneumococcal vaccination was associated with a lower risk of bacteremia (odds ratio 0.46, 95% CI 0.22–0.98). Compared with unvaccinated patients, vaccine recipients had better clinical outcomes, which included a faster resolution of pneumonia symptoms. The median length of hospital stay was shorter in vaccinated patients (8.0 vs. 9.0 days; p=0.032). Overall case-fatality rates did not differ significantly between groups (1.6% vs. 6.2%; p=0.233). In conclusion, prior pneumococcal vaccination appears to be associated with a lower risk of bacteremia, a faster time to resolution of symptoms, and a shorter hospital stay in adults with pneumococcal pneumonia. The findings presented here provide additional support to the current vaccine recommendations and should encourage healthcare providers to increase pneumococcal vaccine coverage among targeted adult populations.
Similar content being viewed by others
References
Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG (2005) The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 192:377–386
Gutierrez F, Masia M, Rodriguez JC, Ayelo A, Soldan B, Cebrian L, Mirete C, Royo G, Hidalgo AM (2003) Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 36:286–292
Pachón J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A (1990) Severe community-acquired pneumonia. Etiology, prognosis, and treatment. Am Rev Respir Dis 142:369–373
Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ (2000) Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 31:347–382
Ramirez JA, Bordon J (2001) Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 161:848–850
Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH (2000) Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 90:223–229
Garau J (2002) Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis 2:404–415
Whitney CG, Schaffner W, Butler JC (2001) Rethinking recommendations for use of pneumococcal vaccines in adults. Clin Infect Dis 33:662–675
Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW (2003) Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 348:1747–1755
Domínguez A, Salleras L, Fedson DS, Izquierdo C, Ruíz L, Ciruela P, Fenoll A, Casal J (2005) Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin Infect Dis 40:1250–1257
Örtqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, Lindblad I, Sundelof B, Kalin M (1998) Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 351:399–403
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250
National Committee for Clinical Laboratory Standards (2004) Performance standards for antimicrobial susceptibility testing. Fourteenth informational supplement. Document M100-S14. NCCLS, Wayne, Pennsylvania, USA
Centers for Disease Control and Prevention (1997) Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 46 (RR-8):1–24
Ament A, Baltussen R, Duru G, Rigaud-Bully C, de Graeve D, Ortqvist A, Jonsson B, Verhaegen J, Gaillat J, Christie P, Cifre AS, Vivas D, Loiseau C, Fedson DS (2000) Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 31:444–450
Greci LS, Katz DL, Jekel J (2005) Vaccinations in pneumonia: pneumococcal and influenza vaccination patterns among patients hospitalized for pneumonia. Prev Med 40:384–388
Musher DM, Alexandraki I, Graviss EA, Yanbeiy N, Eid A, Inderias L, Phan H, Solomon E (2000) Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore) 79:210–221
Centers for Disease Control and Prevention (1997) Missed opportunities for pneumococcal and influenza vaccination of Medicare pneumonia inpatients—12 western states, 1995. MMWR Morb Mortal Wkly Rep 46:919–923
Nichol KL, MacDonald R, Hauge M (1997) Side effects associated with pneumococcal vaccination. Am J Infect Control 25:223–228
Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG (2003) Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 138:960–968
Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR (2001) Early switch and early discharge strategies in patients with community-acquired pneumonia. A meta-analysis. Arch Intern Med 161:722–727
Acknowledgements
The authors thank Manel Oviedo for statistical analyses. They also thank the staff members, fellows, and residents of the Infectious Disease, Respiratory, Medicine, and Microbiology Services of the Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Universitari de Bellvitge, for their valuable cooperation. Research grants were received from the Spanish National Health Service (Fondo de Investigación Sanitaria de la Seguridad Social, grants 040139, 040151, 041835, and ISCiii-RTIC 03/011 [RED RESPIRA]); the Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Universitari de Bellvitge (2003–2004; to A.M.); and the Universitat de Barcelona, Beca de Formació en la Recerca i la Docència (2000; to N.F-S).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mykietiuk, A., Carratalà, J., Domínguez, A. et al. Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 25, 457–462 (2006). https://doi.org/10.1007/s10096-006-0161-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-006-0161-8